Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA.
Dietz S, Christopoulos P, Yuan Z, Angeles AK, Gu L, Volckmar AL, Ogrodnik SJ, Janke F, Fratte CD, Zemojtel T, Schneider MA, Kazdal D, Endris V, Meister M, Muley T, Cecchin E, Reck M, Schlesner M, Thomas M, Stenzinger A, Sültmann H.
Dietz S, et al.
EBioMedicine. 2020 Dec;62:103103. doi: 10.1016/j.ebiom.2020.103103. Epub 2020 Nov 9.
EBioMedicine. 2020.
PMID: 33161228
Free PMC article.